Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus
The purpose of this research study is to find out whether dexmedetomidine changes brain cell activity in the subthalamic nucleus (STN).
In order to find whether dexmedetomidine is optimal for sedation during Deep brain stimulation surgery, we will measure the electrical activity in the STN during Deep brain stimulation surgery, and measure how this activity is changed during administration of Dexmedetomidine. We hypothesize that dexmedetomidine does not change the firing rate and pattern in the STN.
Deep Brain Stimulation Surgery
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Effects of Dexmedetomidine on Neuronal Activity in the Subthalamic Nucleus During Deep Brain Stimulation Electrode Implantation Surgery|
- Change in average firing rate and pattern in the STN [ Time Frame: 20-35 minutes following drug administration ] [ Designated as safety issue: No ]We will calculate the root mean square (RMS) of the electrical activity as a measure of the spiking rate of neurons in the vicinity of the electrode tip.
- Time to achieve optimal sedation [ Time Frame: 20-35 minutes following drug administration ] [ Designated as safety issue: No ]
- Time to recovery [ Time Frame: 20-35 minutes following drug administration ] [ Designated as safety issue: No ]Time it takes for the patient to become alert after drug administration is stopped.
- Time to recovery of the neuronal activity [ Time Frame: 20-35 minutes following drug administration ] [ Designated as safety issue: No ]Only if the drug actually change the neuronal activity.
|Study Start Date:||November 2012|
|Estimated Study Completion Date:||October 2014|
|Estimated Primary Completion Date:||October 2014 (Final data collection date for primary outcome measure)|
Administration of dexmedetomidine during the Microelectrode recording part of STN electrode implantation surgery.
Dexmedetomidine infusion will be started with a loading dose of 1 mcg/Kg over ten to 20 minutes followed by a maintenance infusion of 0.7 mcg/Kg/hr until stable sedation is achieved.
Other Name: Precedex
Please refer to this study by its ClinicalTrials.gov identifier: NCT01721460
|Contact: Aeyal Raz, MD, PhDfirstname.lastname@example.org|
|United States, Wisconsin|
|University of Wisconsin - Madison, School of Medicine and Public Health||Not yet recruiting|
|Madison, Wisconsin, United States, 53705|
|Principal Investigator: Raz Aeyal, MD, PhD|
|Sub-Investigator: Banks I Matthew, PhD|
|Sub-Investigator: Joel Johnson, MD, PhD|
|Sub-Investigator: Robert Pearce, MD, PhD|
|Sub-Investigator: Deborah Rusy, MD|
|Sub-Investigator: Frank Sasse, MD|
|Sub-Investigator: Karl Sillay, MD|
|Principal Investigator:||Aeyal Raz, MD, PhD||University of Wisconsin, Madison, Department of anesthesiology|